There seems to be an increasing degree of acknowledgement in the medical literature that these lower limb amputations are drug-class side effects of SGLT2 inhibitors class diabetes medicines such as Jardiance and Farxiga in addition to Invokana.
For example, from this recent Medscape news report, “Canagliflozin (Invokana) Gets FDA Nod for CV Protection” there is this summary-type statement:
As with other SGLT2 inhibitors, [Invokana (canagliflozin)] may increase the risk of lower-limb amputations. The FDA added a boxed warning to the [Invokana (canagliflozin)] label last year. [Emphasis added]
For on overview of how and why there is an apparent elevated risk of below-knee lower extremity (BKLE) amputations for Jardiance as well as Farxiga and other SGLT2 inhibitors diabetes drugs, you can review one of our brief pieces about this topic on our Drug Injury Law information page.
Over the past year we have been investigating drug injury lawsuits for patients who have had lower extremity amputations (legs, feet, toes) while using Invokana, Jardiance, Farxiga, or one of the other SGLT-2 inhibitors. And given the direction that the medical literature appears to being going in, we will continue to do so.[View article at original source]
Strictly Confidential, No Obligation.